Explore our flagship validated research methodologies, clinical evaluation services, and high-purity active ingredient manufacturing modules.
Navigating the global regulatory renaissance, consumer demand for clinical verification, and high-yield phytochemical engineering.
The global pharmaceutical and nutraceutical landscape has permanently moved beyond opaque "10:1" or "20:1" crude dry extract claims. Regulatory bodies including the US FDA (21 CFR Part 111 & Part 312 Botanical Drug Guidance) and the European Medicines Agency (EMA HMPC) enforce rigorous batch-to-batch chemical fingerprints, quantitative marker thresholds, and definitive mechanism-of-action profiles.
MedGence bridges this gap by offering precision ODM herbal actives characterized by validated HPLC, GC-MS, and LC-MS/MS chromatographic fingerprints, ensuring our global enterprise clients obtain fully traceable active substances.
Today's wellness consumers and medical practitioners scrutinize ingredient labels with unprecedented scientific literacy. The demand for evidence-based botanical remedies has made human pharmacokinetic data and cellular bioassays mandatory for market leadership.
Our integrated contract research and manufacturing organization (CRO/CDMO) model delivers complete scientific documentation—from in vitro cellular receptor assays and in vivo metabolic pathway identification to Phase I–IV clinical studies—empowering consumer healthcare brands to legally substantiate health claims across tier-1 markets.
Unlike single-molecule synthetic APIs that often suffer from off-target toxicity or drug resistance, botanical actives operate via multi-component, multi-target pharmacology. Traditional Chinese Medicine (TCM) and world ethnomedicines embody centuries of human empirical validation.
MedGence modernizes this ancient wisdom. Having modernized 83 classic TCM formulas and developed 22 novel natural medicine candidates, we apply molecular docking, network pharmacology, and targeted fractionation to isolate the exact molecular drivers of therapeutic efficacy.
A rigorous research infrastructure serving leading hospital systems, multinational pharmaceutical groups, and high-growth supplement innovators.
Custom-engineered botanical actives calibrated for regulatory compliance, stability, bioavailability, and organoleptic properties across key global consumer sectors.
Engineered for instant dissolution, thermal stability, and clean taste profiles in effervescent tablets, gummies, RTD beverages, and powdered drink mixes.
High-purity botanical API fractions manufactured under strict cGMP protocols, suitable for DMF filing, IND botanical applications, and licensed OTC medicines.
Bioactive polyphenols, saponins, and flavonoids purified to eliminate color contamination, formulated for superior stratum corneum penetration and anti-inflammatory activity.
Antibiotic-replacement botanical concentrates designed for poultry, swine, and companion animal feed, boosting intestinal mucosal immunity and feed conversion efficiency.
From initial phytochemistry exploration through animal bioassays, analytical standardization, and multi-metric commercial batches.
Utilizing high-density phytochemical libraries, high-performance liquid chromatography, and high-throughput enzymatic bioassays to isolate specific compounds (alkaloids, polysaccharides, saponins, triterpenes) that activate your biological target mechanism.
Quantifying seasonal fluctuation and geo-climatic variation (Daodi authenticity). We benchmark active marker levels across dozens of cultivation zones to guarantee the lowest cost per gram of active compound.
Developing and validating quantitative and qualitative testing protocols under ICH Q2(R1) guidelines, including high-performance thin-layer chromatography (HPTLC), HPLC-DAD, GC-MS, and multi-wavelength fingerprinting.
Optimizing critical process parameters (CPPs) across pretreatment, solid-liquid countercurrent extraction, column chromatography resin absorption, membrane nanofiltration, and low-temperature vacuum crystallization.
Resolving hygroscopicity, oxidation vulnerability, low aqueous solubility, and formulation incompatibilities during secondary manufacturing of oral solutions, softgels, micro-tablets, and multi-layer capsules.
Providing acute oral toxicity (LD50 determination), sub-chronic repeat-dose 90-day toxicology, Ames bacterial reverse mutation tests, in vitro mammalian chromosomal aberration, and micronucleus assays to guarantee consumer safety.
Rapid mechanism screening via target cell lines (e.g., RAW264.7 macrophage anti-inflammation, HepG2 glucose metabolism, 3T3-L1 adipogenesis, human dermal fibroblasts for collagen induction) generating rapid go/no-go developmental clarity.
In vivo pharmacodynamic and pharmacokinetic evaluations in validated disease models (spontaneous hypertension, induced hyperglycemia, memory deficit models, arthritis) generating quantitative in vivo efficacy proof points.
Organizing human pharmacokinetic dose-escalation trials, GCP-compliant multi-center Phase I through IV clinical research for New Drug Applications (NDA), and randomized double-blind placebo-controlled human trials for dietary claims.
Leveraging deep TCM synergy models (Jun-Chen-Zuo-Shi principle) and contemporary network biology to synthesize multi-herb therapeutic formulations that achieve therapeutic efficacy without synthetic side effects.
From continuous automated pilot scale to multi-ton commercial extract batches. Supply forms: standardized liquid concentrates, microencapsulated free-flowing powders, purified semi-solid pastes, and CO2 supercritical volatile oils.
Full CDMO delivery of finished products: blister-packaged hard gelatin/vegetable capsules, laser-drilled osmotic tablets, nitrogen-flushed oral liquid ampoules, softgels, stick packs, and micro-granules under pharmaceutical GMP oversight.
How MedGence integrates artificial intelligence, green extraction chemistries, and bio-nanotechnology to pioneer 2025–2030 botanical manufacturing.
Traditional drug discovery takes decades. By training proprietary machine learning models on tens of thousands of herbal extracts, clinical trial histories, and mass spectrometry spectra, MedGence can simulate compound-target binding affinity in minutes. We predict human receptor interactions, Cytochrome P450 inhibition, and blood-brain barrier permeability before wet lab synthesis begins.
High Information Gain ProtocolEliminating toxic organic solvents (hexane, chloroform, dichloromethane) is both an ecological and regulatory imperative. Our continuous supercritical carbon dioxide (scCO2) and subcritical water extraction systems operate under low thermal stress, preserving delicate terpenes, thermolabile polyphenols, and essential volatile oils while leaving zero solvent residues.
Zero Solvent Residue GuaranteeTraditional batch chromatography suffers from solvent waste and variable purity. MedGence employs continuous Simulated Moving Bed (SMB) industrial chromatography, allowing continuous binary or multi-fraction separation of structurally identical isomers and high-value glycosides at >99% purity thresholds with 60% lower solvent consumption.
Industrial-Scale Purity >99%Hydrophobic herbal actives (such as curcuminoids, silymarin, quercetin, and ginsenosides) frequently suffer from poor oral absorption and rapid first-pass liver clearance. Our pharmaceutical formulation laboratory manufactures liposomal vesicles, phospholipid complexes (phytosomes), and self-emulsifying drug delivery systems (SEDDS) that demonstrate up to 10-fold oral bioavailability improvements in animal and human clinical trials.
Pharmacokinetic SuperiorityCapitalizing on deep agronomic origins, vertically integrated manufacturing clusters, and rapid turnaround advantages.
China is home to over 11,000 medicinal plant species. MedGence maintains direct partnerships with Good Agricultural Practices (GAP) compliant cultivation cooperatives in specialized botanical ecosystems across Hunan, Yunnan, Sichuan, and Anhui. This ensures complete supply-chain resilience, unadulterated botanical identity, and full harvest trace integrity from field to extract.
A classic bottleneck in botanical product development is the failure to scale from benchtop 500mL flasks to 10,000L industrial extractors. Our technical infrastructure operates twin pilot plants directly overseen by our senior analytical team. Process parameters established in research transition without deviation to commercial contract manufacturing.
By co-locating extraction infrastructure, state-of-the-art analytical equipment (LC-MS/MS, ICP-MS for heavy metals, GC-MS for pesticide screening), and packaging facilities, we eliminate multi-vendor logistics markups. Clients achieve a 30% to 50% cost advantage over Western contract facilities while securing faster pilot batch deliveries.
Ensuring frictionless border clearance and compliant product filings in the USA, European Union, UK, Japan, Australia, and ASEAN.
Every active ingredient lot is supplied with a comprehensive Certificate of Analysis (CoA) conforming to USP, Ph. Eur., BP, or ChP requirements. Assays include quantified active markers, residual solvents (USP <467>), heavy metals by ICP-MS (USP <232> / <233>), aflatoxins, and 400+ pesticide residue screens.
We provide full CMC (Chemistry, Manufacturing, and Controls) support, including stability testing data (accelerated and long-term according to ICH Q1A), process validation reports, and raw data required for FDA New Dietary Ingredient Notifications (NDIN), GRAS self-affirmations, or botanical Drug Master Files (DMF).
We operate exclusively on an entrusted research and manufacturing model. Under our legally binding NDA protocols, client formulations, target indications, customized extraction parameters, and proprietary compounds remain your exclusive intellectual property. We do not market competing finished consumer brands.
Our scientific methodologies and quality systems power research and product portfolios for 33+ renowned pharmaceutical giants and clinical institutions.
China Beijing Tongrentang Group
China Resources Sanjiu Medical
Sunflower Pharmaceutical Group
Livzon Pharmaceutical Group Inc.
Dihon Pharmaceutical Group
Golden Throat Holdings Group
Yangtzi River Pharmaceutical
Beihai Gofar Biological
Humanwell Healthcare Group
SCIMYTH Pharmaceutical Group
Shandong Hanfang Pharma
Luoxin Pharmaceutical Group
Guangdong Zhongsheng Pharma
Brilliance & Abundance TCM
Apeloa Pharmaceutical
Hunan Heng Chang Pharma
Baotou TCM Co., Ltd.
Kamp Medicine Co., Ltd.
Guangxi Santo Pharmaceutical
Hunan Kangshou Pharma
Jiangxi Juwang Pharma
Beijing Tcmages Pharma
Guizhou Ruihe Pharmaceutical
Anhui CR Jinchan Pharma
Kangmei Pharmaceutical Co.
Hunan Tianjicaotang Pharma
Jiangxi Kingstone Unite
Shuguang Hospital (Shanghai TCM)
Hunan Province Affiliated TCM Hospital
First Hospital of Hunan Univ. of CM
Second Xiangya Hospital (CSU)
Second Hospital of Hunan Univ. of CM
Orthopedics of TCM Zhuzhou City
Direct scientific answers covering analytical validation, contract research execution, scale-up protocols, and IP custody.
Accelerate your next product launch with our specialized research, testing, and contract manufacturing solutions.
Connect directly with our senior phytochemists and CDMO project managers to design your custom study package, screening protocol, or commercial production run under full non-disclosure.
